Coherus Oncology (CHRS) Gross Profit: 2013-2025
Historic Gross Profit for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $7.8 million.
- Coherus Oncology's Gross Profit rose 136.23% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.4 million, marking a year-over-year increase of 696.41%. This contributed to the annual value of $149.4 million for FY2024, which is 52.07% up from last year.
- Latest data reveals that Coherus Oncology reported Gross Profit of $7.8 million as of Q3 2025, which was up 14.45% from $6.9 million recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Gross Profit ranged from a high of $136.7 million in Q4 2024 and a low of $869,000 during Q1 2024.
- Over the past 3 years, Coherus Oncology's median Gross Profit value was $7.8 million (recorded in 2025), while the average stood at $24.3 million.
- Within the past 5 years, the most significant YoY rise in Coherus Oncology's Gross Profit was 1,865.33% (2024), while the steepest drop was 94.42% (2024).
- Quarterly analysis of 5 years shows Coherus Oncology's Gross Profit stood at $61.2 million in 2021, then plummeted by 49.14% to $31.1 million in 2022, then crashed by 77.67% to $7.0 million in 2023, then surged by 1,865.33% to $136.7 million in 2024, then surged by 136.23% to $7.8 million in 2025.
- Its Gross Profit stands at $7.8 million for Q3 2025, versus $6.9 million for Q2 2025 and $4.9 million for Q1 2025.